What We Are Trying to Accomplish: To continue funding for the National Institutes of Health (NIH) and Multiple Sclerosis Congressionally Directed Medical Research Program (CDMRP) to help find prevent, treat and find a cure for MS, as well as ensure that the U.S. Food and Drug Administration (FDA) has enough resources to meet its goals of protecting the public’s health.
Why It’s Important: The NIH is the country’s premier institution for health research and the single largest source of funding for MS research projects in the world. The MS CDMRP provides additional research funding for research projects focused on MS. Congress determines how much funding these programs receive every year.
The FDA is responsible for ensuring many consumer products are safe to be used or consumed. In relation to health care, they review all drugs and medical devices before they are available to the public. During this review, FDA will determine whether these therapies are safe and effective. Adequate funding is needed to ensure therapies are evaluated in a timely manner so that they can get to patients.
Updates: In mid-December 2015, Congress completed the Fiscal Year 2016 budget. In it, the NIH received a $2 billion increase over last year's funding level--for a total of $32.1 billion. The MS CDMRP received a $1 million increase--for a total of $6 million. The FDA received a $120 million increase--for a total of $2.72 billion. These are impressive increases that will help stop MS in its tracks, restore what has been lost and help end MS forever.
Check back soon for fiscal year (FY) 2016 action alerts on MS research funding.